Savara Announces Resignation of Chief Medical Officer

AUSTIN, Texas--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Badrul Chowdhury, M.D., Ph.D., has resigned from his role as Chief Medical Officer, effective September 9, 2022.

“We appreciate Dr. Chowdhury’s contributions during his tenure with the company,” said Matt Pauls, Chair and CEO, Savara. “His leadership helped progress our molgramostim nebulizer solution (molgramostim) development program through some important milestones and we wish him well in the future.”

“I am pleased to have been part of the Savara team and wish the company success in the continued development of molgramostim for the treatment of the rare lung disease autoimmune pulmonary alveolar proteinosis,” said Dr. Chowdhury. “I leave Savara with continued confidence in the pivotal Phase 3 IMPALA-2 trial.”

About Savara

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com. (Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).

View source version on businesswire.com: https://www.businesswire.com/news/home/20220826005075/en/

Savara Inc. IR & PR

Anne Erickson

Senior Vice President, Chief of Staff

anne.erickson@savarapharma.com

(512) 851-1366

Source: Savara Inc.

FAQ

What are the implications of Badrul Chowdhury's resignation for Savara (SVRA)?

Chowdhury's resignation could raise continuity concerns during crucial trial phases, but his prior leadership helped advance key drug developments.

Who will succeed Badrul Chowdhury as Chief Medical Officer at Savara (SVRA)?

The press release does not specify a successor for Chowdhury's role.

What is the status of the IMPALA-2 trial after Chowdhury's departure?

Despite Chowdhury's resignation, he expressed confidence in the IMPALA-2 trial's continuation.

What is molgramostim and its significance for Savara (SVRA)?

Molgramostim is Savara's lead product in Phase 3 development for treating autoimmune pulmonary alveolar proteinosis.